BioSpace News Archive

Geron Corporation announced that it will release its second quarter and year to date 2021 financial results after the market closes on Monday, August 16, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors.

Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2 mg/mL) available as 1 mL or 5 mL Single-Dose Vials, (AP rated generic equivalent of Isuprel®), and has immediately begun commercialization activity.

Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, announced financial results for the three months ending June 30, 2021.

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced financial results for the second quarter that ended June 30, 2021 and provided a business update.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, mourns the passing of Tadataka “Tachi” Yamada, M.D., the chair of the company’s board of directors.

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced the pricing of its initial public offering of 18,200,000 shares of common stock at a price to the public of $17.00 per share.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), and Eli Lilly and Company (NYSE: LLY) today announced new and updated data from the ORIENT-11 study demonstrating a sustained survival benefit of sintilimab in combination with pemetrexed and platinum chemotherapy in the first-line treatment of patients with nonsquamous non-small cell lung cancer.